TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01882868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
Study: NCT04544683

Intervention type: DRUG
Group type: OTHER
Intervention: Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate
Description: Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
Study: NCT02593825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START-Play intervention
Description: The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as usual
Description: May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
Study: NCT03071289

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Method B
Description: The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: The regimen of chemotherapy is cisplatin 30mg/m2 every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The regimen of chemotherapy is cisplatin 30mg/m2 every week.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Method A
Description: The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
Study: NCT03618316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: 2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: 400 mg of cimetidine bid from Day 5 to Day 10
Study: NCT04119596

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing
Description: Taking a stool sample for gut microbiome DNA sequencing
Study: NCT05638529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnyl (1,500) IU
Description: Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1.5 mL of normal saline
Description: Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
Study: NCT03958409

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measurements to evaluate metabolic bone disease
Description: The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
Study: NCT04647929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Santen PRESERFLO MicroShunt
Description: the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
Study: NCT02143609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m
Study: NCT02143609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m
Study: NCT04119596

Intervention type: GENETIC
Intervention: DNA-microarray genotyping
Description: Taking a saliva sample for genotyping

Intervention type: GENETIC
Intervention: DNA-microarray genotyping
Description: Taking a saliva sample for genotyping
Study: NCT02364934

Intervention type: DRUG
Intervention: Propofol
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.

Intervention type: DRUG
Intervention: Propofol
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
Study: NCT02143609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sham oxygen (room air)
Description: Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham oxygen (room air)
Description: Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
Study: NCT02364934

Intervention type: DRUG
Intervention: Propofol
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.

Intervention type: DRUG
Intervention: Propofol
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.

Intervention type: DRUG
Intervention: Sevoflurane
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Study: NCT03102931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced ROS/RNS content products
Description: Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical to high (ROS/NOS) products
Description: Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
Study: NCT00489554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses.
Study: NCT02952339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 1030s vaccine
Description: 10\^5.0 PFU; administered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as nose drops
Study: NCT00696852

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, Relaxation, and Health Education
Description: The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
Study: NCT02175420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TFV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TFV
Study: NCT02989350

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM 17938 vs Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactobacillus reuteri DSM 17938 vs Placebo
Study: NCT00489554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral, 2 doses.
Study: NCT00925548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25) and Hormonal Treatment
Description: Investigational Arm:~Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~\*calculated as mass of lipopeptide (antigen)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of tecemotide (L-BLP25) and Hormonal Treatment
Description: Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride (NaCl)
Description: NaCl 9 g/L infusion
Study: NCT02364934

Intervention type: DRUG
Intervention: Sevoflurane
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.

Intervention type: DRUG
Intervention: Sevoflurane
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.

Intervention type: DRUG
Intervention: Sevoflurane
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Study: NCT03219411

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamon
Description: Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered orally as capsules three times a day over 12 weeks
Study: NCT04214678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater clip closure
Description: Closure of post-resection defect with endoscopic clips by underwater technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional clip closure
Description: Closure of post-resection defect with endoscopic clip by conventional technique
Study: NCT03788096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support with Motivational Interviewing
Description: Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
Study: NCT04647929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
Study: NCT02159911

Intervention type: DRUG
Intervention: Misoprostol administered orally one hour before surgery
Description: Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient.
Study: NCT02759081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap-assisted water exchange
Description: a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water exchange
Description: water was infused and suctioned at the same time during insertion of colonoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water exchange
Description: water was infused and suctioned at the same time during insertion of colonoscope
Study: NCT01543776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO
Study: NCT03350906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n3-PUFA
Description: The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug but contains soybean oil with no active ingredient.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Body Composition Scan
Description: Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body Composition Scan
Description: Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
Study: NCT01877577

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
Study: NCT02995798

Intervention type: OTHER
Intervention: Cortical Bone thickness and Hounsfield unit (HU) numbers
Description: Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD

Intervention type: OTHER
Intervention: Cortical Bone thickness and Hounsfield unit (HU) numbers
Description: Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD

Intervention type: OTHER
Intervention: Cortical Bone thickness and Hounsfield unit (HU) numbers
Description: Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
Study: NCT01918332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan 160mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin 20mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg placebo
Study: NCT00511316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast/ Singulair
Description: 20 mg daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg daily for 6 months
Study: NCT00731692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
Study: NCT03150628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Description: Perioperative chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreduction
Description: Cytoreductive surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
Study: NCT01324869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KH902
Description: Intravitreal injection of 0.5mg/eye/time KH902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KH902
Description: Intravitreal injection of 0.5mg/eye/time KH902
Study: NCT01575314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stapling device
Description: Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
Study: NCT04267081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Ex vivo venetoclax sensitivity testing is used for patient selection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Ex vivo venetoclax sensitivity testing is used for patient selection.
Study: NCT05702086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)
Description: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)
Description: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.